discussed in the article and noted by the correspondents, this finding was contrasted to the absence of any imbalance in cardiovascular events in the larger placebo-controlled FRAME. These contrasting results have raised questions about the possible cardioprotective effect of alendronate or particular characteristics of the patients in our trial that may have made them more susceptible to cardiovascular events. We agree with Song and Lee that further investigation of this finding is warranted. We agree that osteoporosis treatment is generally intended to be long-term, but because of its time-limited bone-forming effect, romosozumab has been studied as a 1-year course of treatment and is not intended for continuous long-term use. As is good standard practice with all drugs, the benefits and potential risks of the product will have to be carefully assessed in order to make treatment decisions for individual patients.
Both the Prince and Hofbauer groups highlight the role of DKK1 on the vasculature and suggest further investigations to better understand the cardiovascular risk status of the patients in our trial. We have considered examining available spine images for aortic calcification in our trial. Although there is evidence of an association between aortic calcification and the risk of cardiac events in cross-sectional studies, 1 changes in aortic calcification during a timelimited pharmacologic intervention have not been shown to be predictive of a change in the risk of cardiovascular events.
2 As suggested by Hofbauer's group, we measured DKK1 in response to romosozumab in ovariectomized cynomolgus monkeys 3 but found no significant change, which appears to be consistent with earlier findings in a rat model of progressive renal osteodystrophy in which there also was no significant change in DKK1 levels in response to sclerostin antibody treatment. 4 Thus, there is limited biologic plausibility to pursue this association further in humans. 
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To the Editor: CANTOS showed that interleukin-1β inhibition confers a significantly reduced risk of recurrent myocardial infarction. This finding implies that immune-mediated inflammatory diseases, including psoriasis, rheumatoid arthritis, and inflammatory bowel disease, are indeed independent risk factors for incident cardiovascular disease. Beneficial effects of antiinflammatory treatment on the progression of cardiovascular disease and on cardiovascular events have previously been shown among patients with psoriasis in registry-based and cardiovascular imaging studies.
1,2 For clinicians treating inflammation-driven diseases, CANTOS provides arguments for tight disease control through early and aggressive dampening of systemic inflammation to prevent premature development of cardiovascular disease.
3 Although the upstream inhibition of the proinflammatory cascade with canakinumab, in combination with potential safety aspects of interleukin-1 inhibition, could make this particular cytokine target problematic for primary and secondary prevention of cardiovascular disease, the early indications from CANTOS may lead to a radical shift in the management of immunoinflammatory diseases across a wide range of medical specialties. 
To the Editor: CANTOS showed that inhibition of interleukin-1β reduced high-sensitivity C-reactive protein levels and improved clinical outcomes in patients with stable coronary artery disease, indicating that high-sensitivity C-reactive protein is a biomarker of cardiovascular risk and that interleukin-1β is a driver of vascular inflammation. The hazard ratios for the primary end point were 0.93 in the group that received the 50-mg dose of canakinumab, 0.85 in the 150-mg group, and 0.86 in the 300-mg group, but were 0.90, 0.83, and 0.79, respectively, among adherent patients.
The MRC-ILA Heart Study 1 showed effective suppression of high-sensitivity C-reactive protein in non-ST-segment elevation acute coronary syndromes after 14 days of treatment with an interleukin-1 receptor antagonist. However, after discontinuation of the agent, these patients had a higher level of high-sensitivity C-reactive protein at day 30 than patients who had received placebo and a higher rate of major adverse cardiac events at 1 year. Unpublished data from the MRC-ILA Heart Study show that among patients who received the interleukin-1 receptor antagonist, those who had major adverse cardiac events had higher levels of high-sensitivity C-reactive protein at day 1 (baseline), day 14 (end of treatment), and day 30 than those who did not have major adverse cardiac events (Fig. 1) . Clinical and biologic data from nonadherent patients in CANTOS would be informative when physicians consider withdrawal from therapies that target interleukin-1. 
To the Editor: In CANTOS, blocking interleukin-1β reduced the incidence of atherothrombosis and nonfatal stroke, and an additional analysis Panel A shows the geometric mean level of high-sensitivity CRP according to group at days 1 through 7, 14, and 30. Patients who received an interleukin-1 receptor antagonist (IL-1RA) for 14 days had lower levels of highsensitivity CRP at day 14 than those who received placebo. However, at day 30 (16 days after the intervention period), those who had received IL-1RA had higher levels of high-sensitivity CRP than those who had received placebo. Among patients who received IL-1RA, those who had major adverse cardiac events (MACE) had higher levels of high-sensitivity CRP at days 1, 14, and 30 than those who did not have MACE. Panel B shows the high-sensitivity CRP level in individual patients (circles) at days 1, 14, and 30. In the box plots, the horizontal line inside the box indicates the median, the top and bottom of the box indicate the interquartile range, and the I bars indicate the 5th and 95th percentiles. showed that patients who received the 300-mg dose of canakinumab had a total cancer mortality that was lower by 51% than those who received placebo and a lung-cancer mortality that was lower by 77%. 1 The incidence of fatal infection was nearly twice as high in the pooled canakinumab groups as in the placebo group, a finding similar to that observed with the interleukin-1 receptor antagonist anakinra.
2 The accompanying editorial by Harrington 3 discussed the safety risk of interleukin-1β blockade.
Interleukin-1β is driven by multiple inflammasomes. As an alternative to inhibition of interleukin-1β, precise inhibition of a single inflammasome, NLRP3, is likely to be safer. NLRP3 is implicated in diseases of aging, such as atherosclerosis and neurodegenerative disorders. Selective NLRP3 inhibition will leave other inflammasomes to respond to infection. In addition, at the onset of severe infection, an orally available small molecule could be withdrawn, whereas canakinumab cannot. NLRP3 activation also drives interleukin-18, the clinical targeting of which is also safe. Dr. O'Neill reports being the co-founder, the chief scientific officer, and a shareholder of Inflazome, which is developing drugs that target inflammasomes; and Dr. Cooper, being the co-founder, the chief executive officer, and a shareholder of Inflazome. No other potential conflict of interest relevant to this letter was reported. 
To the Editor: The trial by Ridker et al. examined canakinumab in a cohort of patients with established coronary artery disease. Although the reduction in cardiovascular events was significant (hazard ratio, 0.85), the disconcerting results included an increased risk of fatal infection and no mortality benefit. In addition, the drug is expensive ($200,000 per year). The accompanying editorial calls for alternative, more cost-effective antiinflammatory agents without the associated risk of fatal infection.
In a prospective, randomized, secondary-prevention trial, colchicine, an ancient 1 but inexpensive antiinflammatory drug with pleiotropic effects including the targeting of neutrophils, resulted in a reduced rate of recurrent cardiovascular events (hazard ratio, 0.29) without an increase in fatal infection.
2 In light of this finding, it is surprising that this agent was not acknowledged by the authors, because at face value, it seems to fulfill the requirements suggested in the editorial. Although studies of colchicine thus far have been predominantly investigator-initiated and smaller in size, it is to be hoped that ongoing research will confirm the initial promising results with this drug. or fatal infections in the trial and note that perhaps alternative antiinflammatory agents might provide the clinical cardiovascular benefit observed with canakinumab but with a better safety profile. O'Neill and Cooper present the hypothesis that a more specific inhibitor of interleukin-1β, perhaps through inhibition of NLRP3, might prove safer than canakinumab. Certainly, this is a reasonable concept to consider for future investigation.
Nerlekar and Harper express surprise that colchicine was not mentioned in my editorial as an antiinflammatory agent worthy of further investigation, given the findings from a small study (involving 532 patients) that suggested a possible clinical cardiovascular benefit from colchicine among patients with stable coronary artery disease.
1 This trial also showed that 11% of the patients who received colchicine discontinued the treatment in the first 30 days owing to gastrointestinal intolerance. A better understanding of the balance between risks and benefits requires a much larger clinical trial, powered appropriately for the clinical cardiovascular outcomes and with sufficient monitoring for an assessment of safety.
A recent Cochrane meta-analysis on colchicine in heart disease concluded that there was uncertainty regarding its risks and benefits in patients with heart disease but that it was worthy of further investigation.
